Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

ASCO 2020 Virtual Meeting/May 29-31, 2020
EHA 2020 Virtual Meeting/June 11-21, 2020
Listen to Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss the implications of recent trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
John Allan, MD
Jennifer R. Brown, MD, PhD
Released: August 31, 2020

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:

  • ASPEN: Zanubrutinib vs ibrutinib in WM
  • OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL
  • GHSG HD17: PET-guided therapy in HL
  • KEYNOTE-024: Pembrolizumab vs brentuximab in HL
  • ALEXANDER: AUTO3 in DLBCL

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://www.clinicaloptions.com/oncology/conference-coverage/global-asco-eha-2020

Acknowledgements

Supported by an educational grant from
AstraZeneca

Related Content

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Expert insight commentary from Clinical Care Options (CCO) on use of luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) patients

Guillermo Garcia-Manero, MD Released: October 14, 2020

Watch a short video providing an expert view on treatment options after BTK inhibitor– and venetoclax for patients with CLL from Clinical Care Options (CCO)

Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 14, 2020 Expired: October 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue